Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash

Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash
arcticnovartis

  • Novartis secured 79.6 percent acceptance by MorphoSys shareholders during the initial acceptance period, reaching the minimum 65% acceptance threshold
  • Settlement of the shares tendered during the initial acceptance period is expected to occur on 23 May 2024
  • Additional statutory acceptance period is expected to end on 30 May 2024 at 24:00 hours CEST
  • Transaction strengthens the Novartis pipeline in oncology, adding pelabresib, a late-stage BET inhibitor for myelofibrosis and tulmimetostat, an early-stage invest
/by
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo

Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo
arcticnovartis

  • Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs.
/by
Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria

Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria
arcticnovartis

  • Patients treated with remibrutinib experienced improvements in weekly urticaria activity scores (UAS7) observed as early as Week 1 and sustained to 1 year (Week 52)1
  • Remibrutinib, an oral Bruton’s tyrosine kinase inhibitor, demonstrated a favorable and consistent safety profile up to 1 year, including balanced liver function tests versus placebo1
/by
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company’s IgA nephropathy (IgAN) portfolio

Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company’s IgA nephropathy (IgAN) portfolio
arcticnovartis

  • In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1% proteinuria (protein in urine) reduction vs. placebo + supportive care at 36 weeks1
/by
Latest analysis of Novartis NATALEE study shows Kisqali® reduces risk of cancer recurrence for early breast cancer patients with high-risk node-negative disease

Latest analysis of Novartis NATALEE study shows Kisqali® reduces risk of cancer recurrence for early breast cancer patients with high-risk node-negative disease
arcticnovartis

  • Addition of Kisqali® (ribociclib) to endocrine therapy (ET) demonstrated a 28% risk reduction in invasive disease-free survival (iDFS) in subgroup of patients with node-negative (N0) disease at high risk of recurrence1
/by
Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML

Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML
arcticnovartis

  • Phase III ASC4FIRST trial met both primary endpoints with clinically meaningful and statistically significant results; Scemblix® (asciminib) demonstrated superior MMR rates at week 48 vs. investigator-selected SoC TKIs (imatinib, nilotinib, dasatinib and bosutinib) (67.7% vs. 49.0%) and imatinib alone (69.3% vs. 40.2%)1 
/by
Novartis erzielt im zweiten Quartal weiterhin kräftige Umsatzsteigerungen und erhöht die Kerngewinnmarge; Gewinnprognose für das Geschäftsjahr 2024 angehoben

Novartis erzielt im zweiten Quartal weiterhin kräftige Umsatzsteigerungen und erhöht die Kerngewinnmarge; Gewinnprognose für das Geschäftsjahr 2024 angehoben
arcticnovartis

Ad-hoc-Mitteilung gemäss Art. 53 KR

/by
Novartis setzt die starke Dynamik fort mit zweistelligem Umsatzwachstum, robusten Margensteigerungen und mehreren Zulassungen im ersten Quartal

Novartis setzt die starke Dynamik fort mit zweistelligem Umsatzwachstum, robusten Margensteigerungen und mehreren Zulassungen im ersten Quartal
arcticnovartis

Ad-hoc-Mitteilung gemäss Art. 53 KR 

/by
Novartis continues strong momentum with double-digit sales growth, robust margin expansion and multiple approvals in Q1  

Novartis continues strong momentum with double-digit sales growth, robust margin expansion and multiple approvals in Q1  
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

/by
Europe talks health sovereignty — now it must deliver

Europe talks health sovereignty — now it must deliver
angilma1

/by